Esperion's lead candidate shows promise in Type 2 diabetes
This article was originally published in Scrip
Esperion has announced positive Phase II top line results for its hypercholesterolemia product, ETC-1002, in type 2 diabetes. The Plymouth, Michigan-based firm plans to advance the drug through Phase II development and explore the product's efficacy in additional patient populations, particularly those intolerant of statins.
You may also be interested in...
Pharmaceutical industry groups say the European Commission’s Pharmaceutical Strategy Roadmap lacks detail on delivering a faster regulatory process and encouraging competitiveness.
The Australian Therapeutic Goods Administration is consulting on a draft standard for data matrix codes on the labels of certain medicines.
The European Medicines Agency received more requests for scientific advice in 2019 than it did in 2018. Meanwhile, requests for advice in other areas has fallen.